A method for producing a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel, the method comprising: a step 1 of applying a fibrinogen solution containing at least one selected from the group consisting of cells and drugs and fibrinogen dropwise onto a surface of a substrate made of a gelatin hydrogel; a step 2 of adding thrombin to the fibrinogen solution on the surface of the substrate; a step 3 of placing a support film on and in contact with a top surface of the fibrinogen solution to which the thrombin has been added; a step 4 of forming a fibrin sheet containing the at least one selected from the group consisting of cells and drugs in a fibrin gel between the substrate and the support film by a reaction between the fibrinogen and the thrombin; and a step 5 of melting the substrate at a temperature not lower than a melting temperature of the gelatin hydrogel to separate, from the substrate, the fibrin sheet supported by the support film.

The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels. Subsequently, the agent in the supplying channel is replaced with the cell culture medium continuously flowing through the microfluidic device and the cells within the hydrogels are transformed into multicellular spheroids.

A bioadhesive sheet-shaped material configured to be attached onto a surface of an organ, a method for producing the bioadhesive sheet-shaped material, and a method for treating a disease by using the bioadhesive sheet-shaped material. The bioadhesive sheet-shaped material includes an extracellular matrix layer, a sheet-shaped cell culture, and a biodegradable gel layer, where the sheet-shaped cell culture is interposed between the extracellular matrix layer and the biodegradable gel layer, and the bioadhesive sheet-shaped material is by attaching the extracellular matrix layer onto a surface of an organ.

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

A tissue graft for soft tissue repair or reconstruction comprising a sheet of a biopolymer-based matrix having a plurality of small perforations and a plurality of large perforations. The small perforations are sized to facilitate clotting and granulation tissue development within the perforations which, in turn, facilitates revascularization and cell repopulation in the patient. The large perforations are sized to reduce the occurrence of clotting and granulation tissue development within the perforations so that extravascular tissue fluids accumulating at the implant site can drain through the tissue graft. The large perforations enhance mammal tissue anchoring by permitting mammal tissue to compress into the perforations increasing mammal tissue contact area.

[Problem] To provide a method for producing an artificial three-dimensional muscle tissue, said method enabling stable, efficient and easy production of a muscle tissue, and an artificial three-dimensional muscle tissue produced by this method. [Solution] A method for producing an artificial three-dimensional muscle tissue, said method comprising steps of (i) forming a three-dimensional muscle tissue precursor, which is configured from a first muscle tissue support, a second muscle tissue support and muscle cells, by linearly arranging the muscle cells on the first muscle tissue support in such a manner that the muscle cells are located close to the first muscle tissue support at one end of the line and close to the second muscle tissue support at the other end of the line, and (ii) culturing the three-dimensional muscle tissue precursor to give an artificial three-dimensional muscle tissue, and an artificial three-dimensional muscle tissue obtained by this method.

A process of using a fish plasma component in a nutrient medium for cell culture includes obtaining a fish that is a progeny of domesticated broodstock that are reared under consistent and reproducible conditions. Blood is obtained from the fish, and plasma is separated from the blood. One or more specific components of the plasma are then extracted, and cells are cultured in a nutrient medium using the one or more extracted plasma components, and none of any remainder of the plasma. The plasma and/or the plasma components is/are tested for presence and/or level of endotoxin. Extracting the one or more specific components of the plasma, and/or culturing the cells is only performed if the testing indicates an endotoxin level below a predetermined threshold. The cells cultured using the extracted one or more plasma components are other than fish cells.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Methods are provided for the efficient differentiation of hPSCs into HSC-like cells and endothelial cells in defined, monolayer conditions solely using extracellular signals to guide differentiation. The instant disclosure also provides methods of screening for cellular responses of the generated hematopoietic stem cells, endothelial cells and derivatives thereof. Treatment methods making use of the generated hematopoietic stem cells and endothelial cells are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.

The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels. Subsequently, the agent in the supplying channel is replaced with the cell culture medium continuously flowing through the microfluidic device and the cells within the hydrogels are transformed into multicellular spheroids.